SCHEMBL4047573

SCHEMBL4047573

COc1ccc(OC)c(Nc2nc(N)n(-c3ccc(C#N)cc3)n2)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 10/20 0.70
IRAK4 Q9NWZ3 5/20 0.53
KIT P10721 4/20 0.53
AURKA O14965 2/20 0.53
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
MAPT P10636 3/20 0.43
MAPK1 P28482 1/20 0.43
MEN1 O00255 1/20 0.41
USP2 O75604 1/20 0.41
LMNA P02545 1/20 0.41
GAA P10253 1/20 0.41
KMT2A Q03164 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
DHFR P00374 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPKAPK2 P49137 1/20 0.41
PIK3CD O00329 1/20 0.41
BRAF P15056 1/20 0.41
MAP3K5 Q99683 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2088439 0.92 FLT3 (0.67) FLT3IRAK4KITAURKANPC1
SCHEMBL4041596 0.87 FLT3 (0.64) FLT3IRAK4KITAURKANPC1
SCHEMBL4036739 0.83 FLT3 (0.51) FLT3IRAK4KITAURKANPC1
SCHEMBL2088943 0.83 FLT3 (1.00) FLT3IRAK4KITAURKAMAPT
SCHEMBL4042662 0.82 FLT3 (0.72) FLT3IRAK4KITAURKAMEN1
SCHEMBL4038352 0.81 FLT3 (0.80) FLT3IRAK4KITAURKA
SCHEMBL2086558 0.81 FLT3 (0.80) FLT3IRAK4KITAURKA
SCHEMBL4036447 0.81 FLT3 (0.72) FLT3IRAK4KITAURKANPC1
SCHEMBL2088004 0.79 FLT3 (0.62) FLT3IRAK4KITAURKA
SCHEMBL12845572 0.79 FLT3 (0.62) FLT3IRAK4KITAURKAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902239-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-08 US disclosed
US-7902239-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-08 US disclosed
EP-1562589-B1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMA (US) 2009-01-07 EP disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 US disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 US disclosed
CN-1738615-A Diaminotriazoles as inhibitors of protein kinases VERTEX PHARMA (US) 2006-02-22 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES MAP3K20, MAP3K1, MAP3K5 FLT3 220/4885IRAK4 566/4885KIT 1144/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.